Assyro AI

Purple Book product · Reference 351(a)

Susvimo

ranibizumab

351(a)BLA 761197RxLicensed Genentech, Inc.

At a glance

Oct 22, 2021

Approved

Reference 351(a)

License type

Rx

Marketing

No

Patents listed

Key dates

  1. Approval

    Approval date of this BLA submission.

    Oct 22, 2021

    4 yr 8 mo ago

  2. Today

Pharmaceutical detail

Strength

100MG/ML

Dosage form

Injection

Route

Intravitreal

Presentation

Single-Dose Vial

Center

CDER

License number

1048

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.

Patent list (11)

Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
6,716,602Nov 01, 20214 yr 8 mo agoFDA
6,828,121Jul 08, 20224 yr agoFDA
9,688,775Dec 31, 20223 yr 6 mo agoFDA
6,921,659Oct 17, 20232 yr 8 mo agoFDA
8,383,773Dec 13, 20232 yr 6 mo agoFDA
8,574,869Jul 08, 2028in 2 yr 2 moFDA
10,421,984Sep 19, 2033in 7 yr 5 moFDA
9,765,379Mar 10, 2034in 7 yr 11 moFDA
10,017,732Mar 14, 2034in 7 yr 11 moFDA
10,829,732Mar 14, 2034in 7 yr 11 moFDA
10,112,994Nov 05, 2035in 9 yr 7 moFDA

Taxonomy and ontology

10 terms

center

Center for Drug Evaluation and Research

center · CDER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(a)

blaType · 351(a)

application pathway

Section 351(a) Biologic

blaType · 351(a)

product role

Reference or Standalone Biologic

blaType · Reference product

marketing status

Prescription

marketingStatus · Rx

licensure status

Licensed

licensure · Licensed

dosage form

Injection

dosageForm · Injection

source kind

Monthly Download

sourceKind · monthly_download

patent status

No Patent List Provided

patentListProvided · No patent list

  • Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
  • Food and Drug Administrationsource forMonthly Download
  • Biologics License Applicationparent ofSection 351(a) Biologic
  • Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
  • Section 351(a) Biologicmaps to351(a)
  • 351(a)classifiesReference or Standalone Biologic

Source provenance

Source kind · Monthly download
Checked May 28, 2026
FDA release · April 2026
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.